List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2964801/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. JAMA - Journal of the American Medical Association, 2016, 316, 2373.	7.4	813
2	Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance. Journal of the American College of Cardiology, 2014, 63, 2541-2548.	2.8	465
3	An abundant dysfunctional apolipoprotein A1 in human atheroma. Nature Medicine, 2014, 20, 193-203.	30.7	316
4	Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women. Journal of the American College of Cardiology, 2020, 75, 2602-2618.	2.8	175
5	Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience. American Heart Journal, 2013, 166, 597-603.	2.7	154
6	Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. American Heart Journal, 2021, 235, 104-112.	2.7	82
7	The Heart Failure Overweight/Obesity Survival Paradox. JACC: Heart Failure, 2015, 3, 917-926.	4.1	80
8	Unique cardiovascular risk factors in women. Heart, 2019, 105, 1656-1660.	2.9	72
9	Increasing Participation of Women in Cardiovascular Trials. Journal of the American College of Cardiology, 2021, 78, 737-751.	2.8	60
10	Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease. JAMA Cardiology, 2020, 5, 1136.	6.1	59
11	Representation of Women in Cardiovascular Clinical Trial Leadership. JAMA Internal Medicine, 2020, 180, 1382.	5.1	53
12	High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. Diabetes Care, 2014, 37, 3114-3120.	8.6	50
13	Cardiac rehabilitation: A class 1 recommendation. Cleveland Clinic Journal of Medicine, 2018, 85, 551-558.	1.3	50
14	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). American Heart Journal, 2016, 176, 83-92.	2.7	45
15	Gender Differences in Utilization of Effective Cardiovascular Secondary Prevention: A Cleveland Clinic Prevention Database Study. Journal of Women's Health, 2008, 17, 515-521.	3.3	39
16	Impact of Atrial Fibrillation on Exercise Capacity and Mortality in Heart Failure With Preserved Ejection Fraction: Insights From Cardiopulmonary Stress Testing. Journal of the American Heart Association, 2017, 6, .	3.7	36
17	Sex Differences in the Etiology of Surgical Mitral Valve Disease. Circulation, 2018, 138, 1749-1751.	1.6	35
18	Cardioprotective anti-hyperglycaemic medications: a review of clinical trials. European Heart Journal, 2018, 39, 2368-2375.	2.2	34

#	Article	IF	CITATIONS
19	Prognostic Value of Estimated Functional Capacity Incremental to Cardiac Biomarkers in Stable Cardiac Patients. Journal of the American Heart Association, 2014, 3, e000960.	3.7	29
20	Design and Rationale of the <scp>GAUSS</scp> â€2 Study Trial: A Doubleâ€Blind, Ezetimibeâ€Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (<scp>AMG</scp> 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy. Clinical Cardiology, 2014, 37, 131-139.	1.8	25
21	Cardiac Surgery in Women in the Current Era: What Are the Gaps in Care?. Circulation, 2021, 144, 1172-1185.	1.6	25
22	Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. Cardiovascular Drugs and Therapy, 2016, 30, 297-304.	2.6	23
23	Comparison Between the Kansas City Cardiomyopathy Questionnaire and New York Heart Association in Assessing Functional Capacity and Clinical Outcomes. Journal of Cardiac Failure, 2017, 23, 280-285.	1.7	22
24	Comparing SF-36Â [®] scores versus biomarkers to predict mortality in primary cardiac prevention patients. European Journal of Internal Medicine, 2017, 46, 47-55.	2.2	22
25	Basic cerebral anatomy for the carotid interventionalist: The intracranial and extracranial vessels. Catheterization and Cardiovascular Interventions, 2006, 68, 104-111.	1.7	19
26	Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. Cardiovascular Drugs and Therapy, 2018, 32, 365-372.	2.6	19
27	Cardiac risk stratification in cancer patients: A longitudinal patient–patient network analysis. PLoS Medicine, 2021, 18, e1003736.	8.4	19
28	Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN. Atherosclerosis, 2016, 254, 78-84.	0.8	18
29	An invasive strategy is associated with decreased mortality in patients with unstable angina and non–ST-elevation myocardial infarction: GUSTO IIb trial. American Journal of Medicine, 2003, 114, 106-111.	1.5	17
30	Sex Differences in the Age of Diagnosis for Cardiovascular Disease and Its Risk Factors Among US Adults: Trends From 2008 to 2017, the Medical Expenditure Panel Survey. Journal of the American Heart Association, 2020, 9, e018764.	3.7	15
31	Predictors of cardiorespiratory fitness improvement in phase II cardiac rehabilitation. Clinical Cardiology, 2018, 41, 1563-1569.	1.8	13
32	Association of Serum Lipoprotein (a) Levels and Coronary Atheroma Volume by Intravascular Ultrasound. Journal of the American Heart Association, 2020, 9, e018023.	3.7	12
33	Prevalence of Coronary Vasospasm Using Coronary Reactivity Testing in Patients With Spontaneous Coronary Artery Dissection. American Journal of Cardiology, 2019, 123, 1812-1815.	1.6	10
34	Prevalence and Prediction of Obstructive Coronary Artery Disease in Patients Referred for Valvular Heart Surgery. American Journal of Cardiology, 2015, 116, 280-285.	1.6	9
35	The Metabolic Syndrome, Cardiovascular Fitness and Survival in Patients With Advanced Systolic Heart Failure. American Journal of Cardiology, 2018, 122, 1513-1519.	1.6	9
36	The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. Diabetes Care, 2020, 43, e22-e24.	8.6	9

#	Article	IF	CITATIONS
37	Pregnancy-Associated Myocardial Infarction: A Review of Current Practices and Guidelines. Current Cardiology Reports, 2021, 23, 142.	2.9	8
38	Asian Americans and Cardiometabolic Risk. Journal of the American College of Cardiology, 2010, 55, 974-975.	2.8	7
39	Remnant Cholesterol. Circulation: Cardiovascular Imaging, 2021, 14, e012615.	2.6	7
40	Effect of High-Density Lipoprotein Cholesterol Levels on Overall Survival and Major Adverse Cardiovascular and Cerebrovascular Events. American Journal of Cardiology, 2021, 146, 8-14.	1.6	7
41	Carbohydrates: Separating fact from fiction. Atherosclerosis, 2021, 328, 114-123.	0.8	7
42	Preventive Cardiology and Risk Assessment: Beyond LDL. Current Atherosclerosis Reports, 2020, 22, 56.	4.8	6
43	Allâ€cause mortality predicted by peak oxygen uptake differs depending on spirometry pattern in patients with heart failure and reduced ejection fraction. ESC Heart Failure, 2021, 8, 2731-2740.	3.1	6
44	Factors Associated With Revascularization in Women With Spontaneous Coronary Artery Dissection and Acute Myocardial Infarction. American Journal of Cardiology, 2022, 166, 1-8.	1.6	5
45	Expanding the availability of cardiac rehabilitation by offering a virtual option: Forecasting the financial implications. American Journal of Preventive Cardiology, 2022, 10, 100334.	3.0	5
46	LDL-C Targets in Secondary Prevention: How Low Should We Go?. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	4
47	Temporal Trends of Cardiac Outcomes and Impact on Survival in Patients With Cancer. American Journal of Cardiology, 2020, 137, 118-124.	1.6	4
48	Giant Saphenous Vein Graft Aneurysm. Cardiology in Review, 2002, 10, 247-248.	1.4	3
49	Comparison of Long-Term Clinical Outcomes After Drug-Eluting Stenting in Blacks-vs-Whites. American Journal of Cardiology, 2019, 124, 1179-1185.	1.6	3
50	Exercise Ventricular Rates, Cardiopulmonary Exercise Performance, and Mortality in Patients With Heart Failure With Atrial Fibrillation. Circulation: Heart Failure, 2021, 14, e007451.	3.9	3
51	Patients with varying courses of single coronary artery: case series. European Heart Journal - Case Reports, 2021, 5, ytab314.	0.6	3
52	Left Ventricular Hypertrophy in a Runner. Circulation, 2014, 130, 590-592.	1.6	2
53	C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. American Journal of Preventive Cardiology, 2020, 3, 100091.	3.0	2
54	A practical approach to the cholesterol guidelines and ASCVD prevention. Cleveland Clinic Journal of Medicine, 2020, 87, 15-20.	1.3	2

#	Article	IF	CITATIONS
55	Three broken vessels in a peripartum patient: a rare case report of spontaneous triple vessel coronary artery dissection. European Heart Journal - Case Reports, 2020, 4, 1-6.	0.6	1
56	Associations between cardiorespiratory fitness, sex and long term mortality amongst adults undergoing exercise treadmill testing. International Journal of Cardiology, 2021, 342, 103-107.	1.7	1
57	Lipid reduction in acute coronary syndrome: How much, when, and how?. Current Cardiology Reports, 2009, 11, 276-281.	2.9	0
58	Prediabetic Patient Outcomes 8 to 15 Years After Drug-Eluting Coronary Stenting. American Journal of Cardiology, 2021, 149, 21-26.	1.6	0
59	Abstract 19496: A New Exercise Testing Model Performs Better than the Duke Treadmill Score to Identify Patients at Increased Risk for All-cause Mortality. Circulation, 2015, 132, .	1.6	0
60	No Woman Left Behind. Circulation: Heart Failure, 2020, 13, e007782.	3.9	0
61	Spontaneous intramyocardial haematoma in transthyretin cardiac amyloidosis. European Heart Journal - Case Reports, 2022, 6, ytac064.	0.6	0
62	High-Intensity Interval Training vs Moderate-Intensity Continuous Training for Women Undergoing Cardiovascular Rehabilitation. JAMA Cardiology, 0, , .	6.1	0